# WT1 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *WT1* gene encodes a zinc-finger transcription factor crucial for genitourinary development, with germline mutations causing nephropathies like Denys-Drash and Frasier syndromes, and somatic alterations implicated in Wilms tumor and acute myeloid leukemia (AML). - *WT1* exhibits extensive alternative splicing, generating four isoforms (+/- KTS, +/- 17aa insertion), with -KTS isoforms primarily acting as DNA-binding transcription factors and +KTS isoforms exhibiting RNA-binding capabilities and influencing RNA processing. - Pathogenic *WT1* mutations are concentrated in exons 8 and 9, affecting the zinc-finger DNA-binding domain, with specific residues like Arg394 being recurrent hotspots for dominant-negative missense mutations in Denys-Drash syndrome. - In AML and MDS, *WT1* is frequently overexpressed, acting as an oncogene that impedes cellular differentiation, whereas in Wilms tumor, mutations are often inactivating, leading to loss of tumor suppressor function. - Therapeutic strategies targeting WT1 include peptide vaccines (e.g., WT1-126) to elicit cytotoxic T-lymphocyte responses and investigational approaches like TCR-engineered T-cell therapy and small-molecule inhibitors targeting WT1 expression or its protein-protein interactions. --- ## Executive Summary & Key Metadata The **WT1** (Wilms tumor 1) gene encodes a zinc-finger transcription factor that is indispensable for normal genitourinary development and is a master regulator of cellular proliferation, differentiation, and apoptosis. Germline mutations in WT1 cause a spectrum of syndromic and non-syndromic nephropathies, while somatic alterations are implicated in the pathogenesis of Wilms tumor (nephroblastoma), acute myeloid leukemia (AML), and an expanding list of solid tumors. The protein's complex biology is defined by its multiple isoforms, its dual role as a transcriptional activator and repressor, and its post-translational modification landscape. | **Attribute** | **Detail** | | :--- | :--- | | **HGNC Symbol** | WT1 | | **UniProt Accession** | P19544 | | **Representative PDB ID** | true (e.g., 2PRW for zinc-finger domain) | | **Chromosomal Locus** | 11p13 | | **Primary Molecular Function** | Sequence-specific DNA-binding transcription factor (activator/repressor); RNA-binding; protein scaffold | | **Disease & Pathology Associations** | Wilms tumor (nephroblastoma), Denys-Drash syndrome (DDS), Frasier syndrome, isolated focal segmental glomerulosclerosis (FSGS), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Location and Genomic Architecture The *WT1* gene is located on the short arm of chromosome 11 at band **11p13**, a region historically identified through the analysis of constitutional deletions in patients with WAGR syndrome (Wilms tumor, Aniridia, Genitourinary anomalies, mental Retardation) [1]. The gene spans approximately **50 kilobases (kb)** of genomic DNA and is oriented on the minus strand (reverse strand) of the chromosome. The genomic structure is complex, comprising **10 exons** that are subject to extensive alternative splicing, alternative translation initiation, and RNA editing. The core promoter of *WT1* lacks a canonical TATA box but contains multiple GC-rich regions and binding sites for a variety of transcription factors, including Sp1, Egr-1, and GATA factors. The promoter region also contains a CpG island, making its expression susceptible to epigenetic regulation via DNA methylation. Enhancer elements have been identified both upstream and within intronic regions, contributing to the tissue-specific and developmental stage-specific expression patterns observed in the urogenital ridge, mesothelium, and hematopoietic progenitor cells. ### 1.2 Alternative Splicing and Isoform Diversity The primary *WT1* transcript undergoes two major alternative splicing events that generate four distinct protein isoforms. The first splicing event involves exon 5, which encodes a 17-amino acid (aa) insertion. The second event involves the use of an alternative 3' splice site at the end of exon 9, resulting in the inclusion or exclusion of three amino acids: lysine, threonine, and serine (**KTS**). The combination of these two events yields four isoforms: **WT1(+KTS/+17aa)**, **WT1(+KTS/-17aa)**, **WT1(-KTS/+17aa)**, and **WT1(-KTS/-17aa)**. The **-KTS** isoforms have a higher affinity for DNA and function primarily as classical transcription factors. The **+KTS** isoforms, which are more abundant in vivo (with a ratio of approximately 2:1 in favor of +KTS), exhibit reduced DNA-binding affinity but have enhanced RNA-binding capabilities and are localized to nuclear speckles, suggesting a role in RNA processing and post-transcriptional regulation. The 17aa insertion encoded by exon 5 modulates the transcriptional activation potential of the protein and may influence interactions with co-regulators. The precise ratio of these isoforms is critical for normal development; perturbations in the +KTS/-KTS ratio are the underlying cause of Frasier syndrome. ### 1.3 Transcriptional and Post-Transcriptional Regulation *WT1* expression is tightly regulated during development. It is highly expressed in the condensing metanephric mesenchyme, podocytes, Sertoli cells, and granulosa cells. Its expression is downregulated upon terminal differentiation of many cell types but is frequently re-expressed in various cancers. The 3' untranslated region (UTR) of the *WT1* mRNA contains multiple AU-rich elements (AREs) and binding sites for microRNAs (e.g., miR-193a), which contribute to mRNA instability and translational repression. Additionally, the *WT1* gene is subject to genomic imprinting in a tissue-specific manner, although the functional consequences of this are complex and not fully understood. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The WT1 protein is a ~52-54 kDa nuclear phosphoprotein. Its domain architecture is modular, with distinct functional regions from the N-terminus to the C-terminus. - **N-Terminal Transactivation/Repression Domain (aa 1-~300):** This proline- and glutamine-rich region is responsible for both transcriptional activation and repression. It contains a self-association domain, allowing WT1 to homo- and heterodimerize. This region also mediates interactions with numerous co-regulatory proteins, including p53, CBP/p300, and BASP1. The N-terminus is also the site of several critical post-translational modifications, including phosphorylation and sumoylation, which modulate its transcriptional activity. - **Central Domain (aa ~180-250):** This region contains a nuclear localization signal (NLS) and a putative RNA recognition motif (RRM). The RRM is thought to mediate the RNA-binding properties of the +KTS isoforms. - **C-Terminal DNA-Binding Domain (aa ~320-449):** This domain consists of **four C2H2-type zinc fingers**. Zinc fingers 1-3 are the primary determinants of DNA sequence specificity, binding to the consensus sequence **5'-GCG(T/G)GGGCG-3'** (the Egr-1 consensus site). The fourth zinc finger is more divergent and contributes to binding affinity and specificity for a broader range of target sequences. The KTS insertion is located in the linker region between zinc fingers 3 and 4, which explains its profound effect on DNA-binding affinity. ### 2.2 Structural Insights from Crystallography and NMR High-resolution structural information is available for the C-terminal zinc-finger domain. The solution structure of the WT1 zinc-finger domain bound to its cognate DNA (PDB: 2PRW) reveals that the four fingers wrap around the major groove of the DNA helix in a canonical C2H2 fashion. Each zinc finger coordinates a single zinc ion via two cysteine and two histidine residues, stabilizing a ββα fold. Key amino acid residues within the α-helix of each finger make base-specific contacts with the DNA. The linker between fingers 3 and 4 is flexible, and the insertion of KTS in this region is predicted to alter the spatial orientation of finger 4, thereby reducing its ability to make stable contacts with DNA. The N-terminal domain is largely intrinsically disordered, a feature that facilitates its promiscuous interactions with a wide array of protein partners. This disorder-to-order transition upon binding is a hallmark of many transcriptional regulators. ### 2.3 Interactive 3D Visualization To explore the three-dimensional architecture of the WT1 protein, including its zinc-finger coordination and DNA-binding interface, use the interactive visualizer below. This tool allows for the manipulation of the protein structure, highlighting key residues and domains. [Interactive 3D Protein Visualizer: Load WT1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P19544) --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Transcriptional Regulation: A Dual Role WT1 functions as a context-dependent transcription factor, capable of activating or repressing the transcription of its target genes. This dual functionality is determined by the cellular context, the specific isoform expressed, the promoter architecture of the target gene, and the availability of co-regulatory proteins. - **Transcriptional Activation:** WT1 can activate the transcription of genes involved in cellular differentiation and growth arrest, such as *CDKN1A* (p21), *AMH* (anti-Müllerian hormone), and *SRY*. Activation is mediated through recruitment of co-activators like CBP/p300, which possess histone acetyltransferase (HAT) activity, leading to chromatin remodeling and increased promoter accessibility. - **Transcriptional Repression:** WT1 represses the transcription of growth-promoting genes, including *MYC*, *BCL2*, *IGF1R*, and *EGFR*. Repression is achieved through the recruitment of co-repressor complexes, such as the BASP1 complex, which deacetylates histones, leading to a closed chromatin state. The choice between activation and repression is often dictated by the promoter context and the presence of specific cis-regulatory elements. ### 3.2 Key Signaling Pathways and Interactors WT1 is integrated into several major signaling networks. It is a downstream effector of the **Wnt/β-catenin** pathway, where it can modulate the expression of Wnt ligands and receptors. It also interacts with the **p53** tumor suppressor pathway; WT1 can bind to p53 and modulate its transcriptional activity, and conversely, p53 can influence WT1's function. This interaction is critical for the cellular response to DNA damage and apoptosis. The **PI3K/AKT** and **MAPK/ERK** pathways also converge on WT1. Phosphorylation of WT1 by various kinases, including protein kinase A (PKA) and Akt, alters its stability, subcellular localization, and transcriptional activity. For instance, phosphorylation at serine 365 and serine 393 within the zinc-finger region can modulate DNA-binding affinity. ### 3.3 Post-Transcriptional and Non-Transcriptional Functions Beyond its role as a transcription factor, WT1 is involved in **RNA metabolism**. The +KTS isoforms co-localize with splicing factors in nuclear speckles and can bind to specific mRNAs, influencing their splicing, stability, and translation. WT1 has also been shown to be a component of the **spliceosome**. Furthermore, WT1 can act as a **protein scaffold**, bringing together various signaling molecules. This non-transcriptional function is particularly relevant in the cytoplasm, where a fraction of WT1 protein resides. ### 3.4 Protein-Protein Interaction Network The WT1 interactome is extensive. Key interaction partners include: - **Transcriptional Co-regulators:** CBP/p300, BASP1, p53, WTAP (Wilms tumor 1-associating protein). - **Signaling Molecules:** PI3K, Akt, 14-3-3 proteins. - **Splicing Factors:** U2AF65, SF1. - **Structural Proteins:** Par-4, Hsp70. The interaction with **WTAP** is particularly notable. WTAP is a component of the m6A RNA methylation complex, linking WT1 to epitranscriptomic regulation. ```mermaid sequenceDiagram participant L as "Ligand (e.g., Growth Factor)" participant R as "Receptor (RTK)" participant K as "Kinase (e.g., PI3K/Akt)" participant W as "WT1 Protein" participant C as "Co-regulator (e.g., CBP/p300)" participant D as "DNA (Target Gene Promoter)" participant M as "mRNA (Target Gene)" L->>R: Binds and activates R->>K: Activates downstream cascade K->>W: Phosphorylates WT1 W->>W: Conformational change / altered activity W->>C: Recruits co-activator or co-repressor W->>D: Binds to specific response element C->>D: Modifies chromatin (acetylation/deacetylation) D->>M: Activates or represses transcription M->>M: Alternatively spliced / stabilized (via +KTS isoform) ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Germline Mutations and Syndromic Disease Germline mutations in *WT1* are responsible for a spectrum of clinical phenotypes, primarily affecting the kidneys and genitourinary tract. - **Denys-Drash Syndrome (DDS):** Characterized by the triad of diffuse mesangial sclerosis (DMS), early-onset nephrotic syndrome, and genitourinary anomalies (e.g., male pseudohermaphroditism). DDS is most often caused by **dominant-negative missense mutations** in the zinc-finger region, particularly in exon 8 or 9. The most common mutation is **p.Arg394Trp** (R394W) in zinc finger 3. These mutations disrupt DNA binding, and the mutant protein can interfere with the function of the wild-type allele. - **Frasier Syndrome (FS):** Characterized by focal segmental glomerulosclerosis (FSGS), gonadoblastoma, and male pseudohermaphroditism. FS is caused by **intronic point mutations** in the donor splice site of intron 9. These mutations disrupt the alternative splicing of the KTS exon, leading to a reduced ratio of +KTS to -KTS isoforms. The resulting imbalance in isoform ratios disrupts podocyte and gonadal development. - **WAGR Syndrome:** Caused by contiguous gene deletions at 11p13 that include both *WT1* and *PAX6*. Patients present with Wilms tumor, aniridia, genitourinary anomalies, and intellectual disability. - **Isolated FSGS and 46,XY Disorders of Sex Development:** Heterozygous missense mutations, particularly in exons 8 and 9, can also cause non-syndromic FSGS or isolated genitourinary anomalies without the full DDS or FS phenotype. ### 4.2 Somatic Mutations in Cancer - **Wilms Tumor (Nephroblastoma):** Somatic mutations in *WT1* are found in approximately 10-20% of sporadic Wilms tumors. These mutations are often inactivating (frameshift, nonsense) or are the same dominant-negative missense mutations seen in DDS. Loss of heterozygosity (LOH) at 11p13 is a common event, leading to complete loss of WT1 function in the tumor. Tumors with *WT1* mutations often show distinct histology, including stromal-predominant features. - **Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS):** In contrast to Wilms tumor, *WT1* mutations in AML are typically **inactivating** and are found in a small subset of patients. More commonly, *WT1* is **overexpressed** in AML and MDS, where it is thought to act as an oncogene by blocking differentiation and promoting proliferation. The presence of *WT1* mutations in AML is associated with a poor prognosis. ### 4.3 ClinVar Classification and Hotspot Residues The ClinVar database classifies numerous *WT1* variants. Pathogenic and likely pathogenic variants are predominantly located in exons 8 and 9, which encode zinc fingers 2 and 3. Key hotspot residues include: - **Arg394 (R394):** The most frequently mutated residue, with R394W and R394Q being common pathogenic variants causing DDS. - **Arg366 (R366):** Mutations at this residue (e.g., R366H) are also associated with DDS. - **Asp396 (D396):** Mutations here (e.g., D396G) are linked to FS. - **His377 (H377):** Mutations (e.g., H377R) are associated with DDS and Wilms tumor. These arginine and aspartate residues are critical for making base-specific contacts with the DNA backbone and bases. Their substitution disrupts the protein's ability to bind to its target DNA sequences, leading to a loss of transcriptional regulation. --- ## 5. Host-Pathogen & Viral Interactions (If applicable) While WT1 is not a primary target for most viral oncoproteins, its interaction with the cellular environment can be modulated by viral infections, particularly in the context of cancer. - **Human Papillomavirus (HPV):** The HPV E6 and E7 oncoproteins are known to dysregulate cellular pathways, including those controlling the cell cycle and apoptosis. While a direct interaction with WT1 has not been definitively established, HPV E6 can promote the degradation of p53, a key WT1 interaction partner. The loss of p53 could indirectly alter WT1's transcriptional activity and its ability to induce apoptosis. Furthermore, HPV E7 can inactivate the retinoblastoma protein (pRB), leading to increased E2F activity, which may in turn affect the expression of WT1 target genes. - **Epstein-Barr Virus (EBV):** EBV nuclear antigens (EBNAs) and latent membrane proteins (LMPs) can modulate host gene expression. LMP1, a major EBV oncoprotein, activates the NF-κB pathway. NF-κB has been shown to regulate *WT1* expression in some cellular contexts. Therefore, EBV infection could potentially lead to altered WT1 expression levels, contributing to the oncogenic phenotype in EBV-associated malignancies. - **Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV):** These viruses are major risk factors for hepatocellular carcinoma (HCC). WT1 is overexpressed in a subset of HCCs and is associated with poor prognosis. The HBx protein of HBV can activate various signaling pathways, including Wnt/β-catenin and Ras/Raf/MAPK, which are known to regulate WT1 expression or function. Similarly, HCV core protein can modulate cellular signaling. The precise molecular link between these viral proteins and WT1 dysregulation in HCC is an area of active investigation. The primary mechanism by which pathogens interact with WT1 is indirect, through the manipulation of cellular signaling pathways that converge on WT1 regulation. There is no evidence of a viral protein directly binding to and degrading WT1, as is seen with p53 and HPV E6. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors WT1 is a compelling therapeutic target due to its high expression in a wide range of cancers and its low expression in most normal adult tissues. Several therapeutic strategies are being pursued. ### 6.1 Immunotherapy - **WT1 Peptide Vaccines:** The most advanced WT1-targeting strategy is the use of peptide vaccines to elicit a cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells. The HLA-A*02:01-restricted peptide **WT1-126 (RMFPNAPYL)** has been extensively studied in clinical trials for AML, MDS, and solid tumors. These vaccines have shown promising results, including the induction of WT1-specific CTLs and clinical responses, with minimal toxicity. Other peptides, such as WT1-235 (CMTWNQMNL), are also being evaluated. - **Adoptive Cell Therapy (ACT):** T-cell receptor (TCR) engineered T cells targeting WT1 are in early-phase clinical trials. These T cells are genetically modified to express a high-affinity TCR specific for a WT1 peptide presented on HLA molecules. This approach offers a more potent and controlled immune response compared to vaccines. - **Monoclonal Antibodies:** While WT1 is an intracellular protein, antibodies targeting the WT1 peptide presented on the cell surface in the context of HLA (e.g., TCR-like antibodies) are being developed. These antibodies can be used to deliver cytotoxic payloads or to recruit immune effector cells to the tumor. ### 6.2 Small-Molecule Inhibitors Directly targeting the WT1 protein with small molecules is challenging due to its nature as a transcription factor. However, several indirect strategies are being explored: - **Inhibitors of WT1 Expression:** Agents that downregulate *WT1* mRNA or protein levels are being investigated. These include histone deacetylase (HDAC) inhibitors, which can alter chromatin structure and reduce *WT1* transcription. Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) targeting *WT1* mRNA have shown preclinical efficacy. - **Inhibitors of WT1's Protein-Protein Interactions:** Disrupting the interaction between WT1 and its essential co-activators, such as CBP/p300, could inhibit its oncogenic function. Small molecules that block these interactions are in early-stage development. - **Inhibitors of Downstream Effectors:** Since WT1 drives the expression of genes like *MYC* and *BCL2*, targeting these downstream effectors (e.g., with BET inhibitors or BCL2 inhibitors like venetoclax) may be a viable therapeutic strategy in WT1-overexpressing tumors. ### 6.3 Gene Therapy Gene therapy approaches aim to correct the underlying genetic defect in patients with germline *WT1* mutations. This is particularly challenging due to the need for precise editing of a large gene. However, with the advent of CRISPR-Cas9 technology, research is ongoing to develop strategies for correcting specific pathogenic mutations. This approach is still in its infancy and faces significant hurdles, including delivery efficiency and off-target effects. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and links for the *WT1* gene and protein. | **Database** | **Identifier / Accession** | **Link / Notes** | | :--- | :--- | :--- | | **NCBI Gene** | 7490 | [https://www.ncbi.nlm.nih.gov/gene/7490](https://www.ncbi.nlm.nih.gov/gene/7490) | | **Ensembl** | ENSG00000184937 | [https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184937](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184937) | | **UniProt** | P19544 | [https://www.uniprot.org/uniprotkb/P19544/entry](https://www.uniprot.org/uniprotkb/P19544/entry) | | **RCSB PDB** | 2PRW (Zinc-finger domain) | [https://www.rcsb.org/structure/2PRW](https://www.rcsb.org/structure/2PRW) | | **OMIM** | 607102 | [https://www.omim.org/entry/607102](https://www.omim.org/entry/607102) | | **ClinVar** | Gene: WT1 | [https://www.ncbi.nlm.nih.gov/clinvar/?term=WT1%5Bgene%5D](https://www.ncbi.nlm.nih.gov/clinvar/?term=WT1%5Bgene%5D) | | **COSMIC** | WT1 | [https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=WT1](https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=WT1) | | **STRING** | P19544 | [https://string-db.org/network/P19544](https://string-db.org/network/P19544) | | **BioGRID** | 114094 | [https://thebiogrid.org/114094](https://thebiogrid.org/114094) | | **Gene Ontology (GO)** | GO:0003677 (DNA binding), GO:0003700 (TF activity), GO:0005515 (protein binding) | [https://www.ebi.ac.uk/QuickGO/](https://www.ebi.ac.uk/QuickGO/) | --- ## Related Clinical & Scientific Guides * [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway) * [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway) * [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway) ## References [1] Call, K. M., Glaser, T., Ito, C. Y., Buckler, A. J., Pelletier, J., Haber, D. A., Rose, E. A., Kral, A., Yeger, H., & Lewis, W. H. (1990). Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. *Cell*, 60(3), 509–520. [https://doi.org/10.1016/0092-8674(90)90601-A](https://doi.org/10.1016/0092-8674(90)90601-A) [2] Haber, D. A., Sohn, R. L., Buckler, A. J., Pelletier, J., Call, K. M., & Housman, D. E. (1991). Alternative splicing and genomic structure of the Wilms tumor gene WT1. *Proceedings of the National Academy of Sciences of the United States of America*, 88(21), 9618–9622. [https://doi.org/10.1073/pnas.88.21.9618](https://doi.org/10.1073/pnas.88.21.9618) [3] Little, M., Holmes, G., & Bickmore, W. (1999). The molecular genetics of Wilms tumour. *Cancer Surveys*, 25, 233–246. [4] Pelletier, J., Bruening, W., Kashtan, C. E., Mauer, S. M., Manivel, J. C., Striegel, J. E., Houghton, D. C., Junien, C., Habib, R., & Fouser, L. (1991). Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. *Cell*, 67(2), 437–447. [https://doi.org/10.1016/0092-8674(91)90194-4](https://doi.org/10.1016/0092-8674(91)90194-4) [5] Barbaux, S., Niaudet, P., Gubler, M. C., Grünfeld, J. P., Jaubert, F., Kuttenn, F., Fékété, C. N., Souleyreau-Therville, N., Thibaud, E., Fellous, M., & McElreavey, K. (1997). Donor splice-site mutations in WT1 are responsible for Frasier syndrome. *Nature Genetics*, 17(4), 467–470. [https://doi.org/10.1038/ng1297-467](https://doi.org/10.1038/ng1297-467) [6] Yang, L., Han, Y., Suarez Saiz, F., & Minden, M. D. (2007). A tumor suppressor and oncogene: the WT1 story. *Leukemia*, 21(5), 868–876. [https://doi.org/10.1038/sj.leu.2404624](https://doi.org/10.1038/sj.leu.2404624) [7] Oka, Y., Tsuboi, A., Oji, Y., Kawase, I., & Sugiyama, H. (2008). WT1 peptide vaccine for the treatment of cancer. *Current Opinion in Immunology*, 20(2), 211–220. [https://doi.org/10.1016/j.coi.2008.04.009](https://doi.org/10.1016/j.coi.2008.04.009) [8] Huff, V. (2011). Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. *Nature Reviews Cancer*, 11(2), 111–121. [https://doi.org/10.1038/nrc3002](https://doi.org/10.1038/nrc3002) [9] Toska, E., & Roberts, S. G. (2014). Mechanisms of transcriptional regulation by WT1 (Wilms' tumour 1). *Biochemical Journal*, 461(1), 15–32. [https://doi.org/10.1042/BJ20131587](https://doi.org/10.1042/BJ20131587) [10] Sugiyama, H. (2010). WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. *Journal of Immunotherapy*, 33(1), 1–10. [https://doi.org/10.1097/CJI.0b013e3181b6e2a4](https://doi.org/10.1097/CJI.0b013e3181b6e2a4)